>>Signaling Pathways>> Others>>Emixustat hydrochloride (ACU-4429 hydrochloride)

Emixustat hydrochloride (ACU-4429 hydrochloride) (Synonyms: ACU-4429 hydrochloride)

Catalog No.GC33763

에믹서스타트 염산염(ACU-4429 염산염)은 232 ±의 IC50 값으로 11-시스-레티놀 생성을 강력하게 억제합니다. 3nM.

Products are for research use only. Not for human use. We do not sell to patients.

Emixustat hydrochloride (ACU-4429 hydrochloride) Chemical Structure

Cas No.: 1141934-97-5

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$167.00
재고 있음
2mg
US$101.00
재고 있음
5mg
US$184.00
재고 있음
10mg
US$295.00
재고 있음
50mg
US$1,011.00
재고 있음
100mg
US$1,609.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Emixustat hydrochloride strongly inhibits 11-cis-retinol production with IC50 values of 232 ± 3 nM. IC50 value: 232 nM [1]Target: 11-cis-retinolEmixustat hydrochloride is a novel visual cycle modulator, in healthy volunteers. Oral Emixustat was safe and well tolerated when administered once daily for 14 days with minimal systemic adverse events reported. Evaluation of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration.[2]

[1]. Kiser PD, et al. Catalytic mechanism of a retinoid isomerase essential for vertebrate vision. Nat Chem Biol. 2015 Jun;11(6):409-15. [2]. Kubota R, et al. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina. 2014 Mar;34(3):603-9.

리뷰

Review for Emixustat hydrochloride (ACU-4429 hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Emixustat hydrochloride (ACU-4429 hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.